Emergent BioSolutions Hits New 52-Week Low at $4.37 Amid Declining Performance

Emergent BioSolutions, Inc. has reached a new 52-week low, trading at USD 4.37 as of August 10, 2026. This marks a significant decline for the microcap company, which operates within the Pharmaceuticals & Biotechnology sector. Over the past year, Emergent BioSolutions has experienced a performance drop of 30.05%, contrasting sharply with the S&P 500's gain of 21.34%. Despite the recent downturn, the company reported positive financial metrics in its latest half-year results. Operating cash flow peaked at USD 169 million, and net profit was recorded at USD 53.95 million. However, the long-term growth outlook appears less favorable, with an annual operating profit decline of 16.76% over the past five years. Emergent BioSolutions currently holds a market capitalization of USD 420 million, with a price-to-earnings ratio of 6.00 and a price-to-book ratio of 0.80. The company’s return on equity stands at 14.43%, although it has faced challenges with a negative return on equity of -15.10%. As the stock continues to navigate these financial dynamics, its recent low reflects ongoing market pressures.